Orexigen obesity drug meets goals in three studies
Monday, July 20, 2009
SAN DIEGO -- Orexigen Therapeutics Inc. said today that its obesity-drug candidate Contrave met its main goals in three late-stage clinical trials, and also surpassed a Food and Drug Administration requirement for effectiveness.
Subscribe below or log in with your password here.
For more than 115 years, the Southeast Missourian has written the first draft of local history. We have aspired to enrich, entertain, educate and inform. Our core values have remained firm: truth, service, quality, integrity and community. Support our mission.
Join today
Note: Special discounts available to new subscribers only. Print subscriptions may include up to 13 Premium Issues per year, which include special magazines. For each Premium Issue, your account balance will be charged an additional fee in the billing period when the section publishes. This will result in shortening the length of your billing period.